Longitudinal trajectory of circulating microRNA-210-3p and its association with low-dose aspirin use in gestational hypertension and preeclampsia: a pilot study.

IF 3.5 4区 医学 Q3 PERIPHERAL VASCULAR DISEASE
Ming-Ju Wang, Chie-Pein Chen, Nan-Fu Chiu, Fang-Ju Sun, Hsin-Yi Hou, Chen-Yu Chen
{"title":"Longitudinal trajectory of circulating microRNA-210-3p and its association with low-dose aspirin use in gestational hypertension and preeclampsia: a pilot study.","authors":"Ming-Ju Wang, Chie-Pein Chen, Nan-Fu Chiu, Fang-Ju Sun, Hsin-Yi Hou, Chen-Yu Chen","doi":"10.1080/10641963.2026.2616534","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Circulating microRNA-210-3p (miR-210-3p) is a hypoxia-related regulator implicated in placental maladaptation. Its longitudinal behavior across hypertensive disorders of pregnancy (HDP), and whether low-dose aspirin modifies its trajectory, remain insufficiently understood.</p><p><strong>Methods: </strong>This prospective case-control study was conducted between October 2021 and November 2024. Circulating miR-210-3p was measured in the first trimester and at delivery. Aspirin use followed routine clinical practice for preeclampsia prevention. Longitudinal trajectories were examined using generalized estimating equations (GEE) as the primary analytic approach and linear mixed effects models (LMM) as a secondary method.</p><p><strong>Results: </strong>Ninety-four women were enrolled, including 73 controls, 11 with gestational hypertension, and 10 with preeclampsia. miR-210-3p increased significantly from the first trimester to delivery in gestational hypertension (<i>p</i> = 0.003) and preeclampsia (<i>p</i> = 0.006), with no significant change in controls. In the first trimester, gestational hypertension exceeded controls (<i>p</i> = 0.006), and preeclampsia exceeded both groups (both <i>p</i> < 0.001). At delivery, gestational hypertension and preeclampsia remained higher than controls (both <i>p</i> < 0.001), and preeclampsia exceeded gestational hypertension (<i>p</i> = 0.036). GEE demonstrated a significantly slower rise in miR-210-3p among aspirin users with gestational hypertension (<i>p</i> = 0.042), and this association strengthened in sensitivity analysis (<i>p</i> = 0.001). LMM showed a similar, non-significant trend.</p><p><strong>Conclusion: </strong>miR-210-3p exhibited disorder-specific longitudinal patterns across HDP. Aspirin-associated changes were observed in gestational hypertension but not in preeclampsia, suggesting differences in molecular expression trajectories between the two conditions over the course of gestation, while the underlying biological mechanisms remain to be clarified.</p>","PeriodicalId":10333,"journal":{"name":"Clinical and Experimental Hypertension","volume":"48 1","pages":"2616534"},"PeriodicalIF":3.5000,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Hypertension","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10641963.2026.2616534","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/16 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Circulating microRNA-210-3p (miR-210-3p) is a hypoxia-related regulator implicated in placental maladaptation. Its longitudinal behavior across hypertensive disorders of pregnancy (HDP), and whether low-dose aspirin modifies its trajectory, remain insufficiently understood.

Methods: This prospective case-control study was conducted between October 2021 and November 2024. Circulating miR-210-3p was measured in the first trimester and at delivery. Aspirin use followed routine clinical practice for preeclampsia prevention. Longitudinal trajectories were examined using generalized estimating equations (GEE) as the primary analytic approach and linear mixed effects models (LMM) as a secondary method.

Results: Ninety-four women were enrolled, including 73 controls, 11 with gestational hypertension, and 10 with preeclampsia. miR-210-3p increased significantly from the first trimester to delivery in gestational hypertension (p = 0.003) and preeclampsia (p = 0.006), with no significant change in controls. In the first trimester, gestational hypertension exceeded controls (p = 0.006), and preeclampsia exceeded both groups (both p < 0.001). At delivery, gestational hypertension and preeclampsia remained higher than controls (both p < 0.001), and preeclampsia exceeded gestational hypertension (p = 0.036). GEE demonstrated a significantly slower rise in miR-210-3p among aspirin users with gestational hypertension (p = 0.042), and this association strengthened in sensitivity analysis (p = 0.001). LMM showed a similar, non-significant trend.

Conclusion: miR-210-3p exhibited disorder-specific longitudinal patterns across HDP. Aspirin-associated changes were observed in gestational hypertension but not in preeclampsia, suggesting differences in molecular expression trajectories between the two conditions over the course of gestation, while the underlying biological mechanisms remain to be clarified.

循环microRNA-210-3p的纵向轨迹及其与妊娠高血压和子痫前期低剂量阿司匹林的关联:一项初步研究
背景:循环microRNA-210-3p (miR-210-3p)是一种与胎盘适应不良相关的低氧调节因子。其在妊娠高血压疾病(HDP)中的纵向行为,以及低剂量阿司匹林是否改变其轨迹,仍未得到充分了解。方法:该前瞻性病例对照研究于2021年10月至2024年11月进行。在妊娠早期和分娩时检测循环miR-210-3p。阿司匹林的使用遵循预防子痫前期的常规临床实践。纵向轨迹研究采用广义估计方程(GEE)作为主要分析方法,线性混合效应模型(LMM)作为次要分析方法。结果:94名妇女入组,包括73名对照组,11名妊娠期高血压,10名先兆子痫。在妊娠期高血压(p = 0.003)和子痫前期(p = 0.006)患者中,miR-210-3p从妊娠早期到分娩期间显著升高,而对照组无显著变化。在妊娠早期,妊娠高血压超过对照组(p = 0.006),先兆子痫超过两组(p = 0.036)。GEE显示,在阿司匹林使用者中,miR-210-3p在妊娠期高血压患者中的升高明显较慢(p = 0.042),并且这种关联在敏感性分析中得到加强(p = 0.001)。LMM表现出类似的、不显著的趋势。结论:miR-210-3p在HDP中表现出疾病特异性的纵向模式。在妊娠高血压中观察到阿司匹林相关的变化,但在子痫前期没有观察到,这表明在妊娠过程中,这两种情况之间的分子表达轨迹存在差异,而潜在的生物学机制仍有待阐明。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.90
自引率
0.80%
发文量
66
审稿时长
6-12 weeks
期刊介绍: Clinical and Experimental Hypertension is a reputable journal that has converted to a full Open Access format starting from Volume 45 in 2023. While previous volumes are still accessible through a Pay to Read model, the journal now provides free and open access to its content. It serves as an international platform for the exchange of up-to-date scientific and clinical information concerning both human and animal hypertension. The journal publishes a wide range of articles, including full research papers, solicited and unsolicited reviews, and commentaries. Through these publications, the journal aims to enhance current understanding and support the timely detection, management, control, and prevention of hypertension-related conditions. One notable aspect of Clinical and Experimental Hypertension is its coverage of special issues that focus on the proceedings of symposia dedicated to hypertension research. This feature allows researchers and clinicians to delve deeper into the latest advancements in this field. The journal is abstracted and indexed in several renowned databases, including Pharmacoeconomics and Outcomes News (Online), Reactions Weekly (Online), CABI, EBSCOhost, Elsevier BV, International Atomic Energy Agency, and the National Library of Medicine, among others. These affiliations ensure that the journal's content receives broad visibility and facilitates its discoverability by professionals and researchers in related disciplines.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书